Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency

NCT03874013 is registered in ClinicalTrials.gov with OPKO Health, Inc. as lead sponsor.

NCT NCT03874013
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03874013 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label, Randomized, Multicenter, 12-month, Efficacy and Safety Study of Weekly MOD-4023 Compared to Daily Genotropin® Therapy in Japanese Pre-pubertal Children With Growth Hormone Deficiency
Lead sponsor
OPKO Health, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 7, 2017
Completion date
March 6, 2020
Enrollment
44 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

growth hormone deficiency